The OHSU-led SOUL trial has demonstrated that oral semaglutide significantly reduces heart failure events in patients with type 2 diabetes who have a prior history of heart failure — findings published in JAMA Internal Medicine that could reshape prescribing patterns for the estimated 30% of T2D patients who carry concurrent HF diagnoses. The oral formulation is particularly significant because it removes the injection barrier that has limited GLP-1 receptor agonist uptake among patients and providers alike.

The SOUL trial is one of the largest cardiovascular outcomes trials for an oral GLP-1 agonist, and its heart failure subanalysis addresses a clinical question that has dogged the drug class: whether the cardiovascular benefits seen with injectable semaglutide (Wegovy/Ozempic) translate to the oral form (Rybelsus). The answer appears to be yes, and for a particularly high-risk subgroup. Heart failure hospitalizations are among the most expensive episodes in Medicare and commercial insurance — averaging $15,000-$25,000 per admission — making any intervention that reduces them both clinically meaningful and financially significant.

Oregon healthcare providers should take note of the SOUL trial's implications for formulary decisions and prescribing protocols. Cardiologists and endocrinologists managing T2D patients with HF now have Level 1 evidence supporting oral semaglutide as a cardioprotective option. Primary care physicians, who manage the majority of T2D patients, should consider incorporating these findings into shared decision-making conversations — particularly for patients who have refused injectable GLP-1 therapies. Oregon CCOs and health plans will likely face formulary pressure to ensure oral semaglutide access, especially given the state's Medicaid population burden of comorbid diabetes and heart failure.

Watch for whether Oregon CCOs update their preferred drug lists to reflect the SOUL trial data and whether prior authorization barriers for oral semaglutide ease in response.